Achieve Life Sciences

OrganisationROR

Trials

  • NCT07392125

    Phase 3, Not yet recruiting, 800 people, 6 Feb 2026

  • NCT06435221

    Phase 3, Completed, 479 people, 30 May 2024

  • NCT05981768

    Phase 1, Completed, 30 people, 8 Aug 2023

  • NCT05631938

    Phase 1, Completed, 44 people, 30 Nov 2022

  • NCT05566288

    Phase 1, Completed, 27 people, 4 Oct 2022

  • NCT05431387

    Phase 2, Completed, 160 people, 24 Jun 2022

  • NCT05206370

    Phase 3, Completed, 792 people, 25 Jan 2022

  • NCT04576949

    Phase 3, Completed, 810 people, 6 Oct 2020

  • NCT03848208

    Phase 1, Completed, 74 people, 20 Feb 2019

  • NCT03709823

    Phase 2, Completed, 254 people, 17 Oct 2018

  • NCT03509948

    Phase 1, Completed, 13 people, 27 Apr 2018

  • NCT03303911

    Phase 1/2, Terminated, 26 people, 6 Oct 2017

  • NCT03268343

    Phase 1, Completed, 24 people, 31 Aug 2017

  • NCT02423590

    Collaborator, Phase 2, Status unknown, 140 people, 22 Apr 2015

  • NCT01681433

    Collaborator, Phase 2, Terminated, 72 people, 10 Sept 2012

  • NCT01578655

    Phase 3, Completed, 630 people, 17 Apr 2012

  • NCT01497470

    Phase 1, Completed, 36 people, 22 Dec 2011

  • NCT01454089

    Phase 2, Completed, 183 people, 18 Oct 2011

  • NCT01188187

    Phase 3, Completed, 1,022 people, 25 Aug 2010

  • NCT01120470

    Collaborator, Phase 2, Completed, 74 people, 11 May 2010

Named in competing interests

Sources: pubmed.ncbi.nlm.nih.gov